Ladenburg analyst Ahu Demir initiated coverage of Sonnet BioTherapeutics with a Buy rating and $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SONN: